1
|
Jahan K, Sood M, Jain O, Sahoo SC, Bharatam PV. Directed regioselective arylation of imidazo[1,2- a]pyridine-3-carboxamides using Rh(III) catalysis. Org Biomol Chem 2024; 22:7121-7127. [PMID: 39155840 DOI: 10.1039/d4ob01166j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/20/2024]
Abstract
In contrast to previously reported free-radical pathways to functionalize imidazo[1,2-a]pyridines at the C-5 centre, directing group approaches are rare. Herein, we demonstrate a rhodium(III) catalyzed efficient and regioselective strategy for directed C-5 functionalization of imidazo[1,2-a]pyridines using N-methoxyamide as a directing group. This methodology facilitates directed arylation without the necessity for pre-functionalization. It also allows for gram-scale synthesis and post-functionalization.
Collapse
Affiliation(s)
- Kousar Jahan
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar, Punjab, India.
- Lloyd Institute of Management and Technology, Plot No.-3, Knowledge Park-II, Greater Noida, Uttar Pradesh, India-201306
| | - Mehak Sood
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar, Punjab, India.
| | - Osheen Jain
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar, Punjab, India.
| | - Subash C Sahoo
- Department of Chemistry & Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh - 160014, India
| | - Prasad V Bharatam
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar, Punjab, India.
| |
Collapse
|
2
|
Bavo F, Pallavicini M, Appiani R, Bolchi C. Determinants for α4β2 vs. α3β4 Subtype Selectivity of Pyrrolidine-Based nAChRs Ligands: A Computational Perspective with Focus on Recent cryo-EM Receptor Structures. Molecules 2021; 26:molecules26123603. [PMID: 34204637 PMCID: PMC8231201 DOI: 10.3390/molecules26123603] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/08/2021] [Accepted: 06/10/2021] [Indexed: 12/26/2022] Open
Abstract
The selectivity of α4β2 nAChR agonists over the α3β4 nicotinic receptor subtype, predominant in ganglia, primarily conditions their therapeutic range and it is still a complex and challenging issue for medicinal chemists and pharmacologists. Here, we investigate the determinants for such subtype selectivity in a series of more than forty α4β2 ligands we have previously reported, docking them into the structures of the two human subtypes, recently determined by cryo-electron microscopy. They are all pyrrolidine based analogues of the well-known α4β2 agonist N-methylprolinol pyridyl ether A-84543 and differ in the flexibility and pattern substitution of their aromatic portion. Indeed, the direct or water mediated interaction with hydrophilic residues of the relatively narrower β2 minus side through the elements decorating the aromatic ring and the stabilization of the latter by facing to the not conserved β2-Phe119 result as key distinctive features for the α4β2 affinity. Consistently, these compounds show, despite the structural similarity, very different α4β2 vs. α3β4 selectivities, from modest to very high, which relate to rigidity/extensibility degree of the portion containing the aromatic ring and to substitutions at the latter. Furthermore, the structural rationalization of the rat vs. human differences of α4β2 vs. α3β4 selectivity ratios is here proposed.
Collapse
Affiliation(s)
- Francesco Bavo
- Dipartimento di Scienze Farmaceutiche, Universita’degli Studi di Milano, I-20133 Milano, Italy; (F.B.); (M.P.); (R.A.)
- Department of Drug Design and Pharmacology, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - Marco Pallavicini
- Dipartimento di Scienze Farmaceutiche, Universita’degli Studi di Milano, I-20133 Milano, Italy; (F.B.); (M.P.); (R.A.)
| | - Rebecca Appiani
- Dipartimento di Scienze Farmaceutiche, Universita’degli Studi di Milano, I-20133 Milano, Italy; (F.B.); (M.P.); (R.A.)
| | - Cristiano Bolchi
- Dipartimento di Scienze Farmaceutiche, Universita’degli Studi di Milano, I-20133 Milano, Italy; (F.B.); (M.P.); (R.A.)
- Correspondence:
| |
Collapse
|
3
|
Development and therapeutic potential of 2-aminothiazole derivatives in anticancer drug discovery. Med Chem Res 2021; 30:771-806. [PMID: 33469255 PMCID: PMC7809097 DOI: 10.1007/s00044-020-02686-2] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 12/06/2020] [Indexed: 11/01/2022]
Abstract
Currently, the development of anticancer drug resistance is significantly restricted the clinical efficacy of the most commonly prescribed anticancer drug. Malignant disease is widely prevalent and considered to be the major challenges of this century, which concerns the medical community all over the world. Consequently, investigating small molecule antitumor agents, which could decrease drug resistance and reduce unpleasant side effect is more desirable. 2-aminothiazole scaffold has emerged as a promising scaffold in medicinal chemistry and drug discovery research. This nucleus is a fundamental part of some clinically applied anticancer drugs such as dasatinib and alpelisib. Literature survey documented that different 2-aminothiazole analogs exhibited their potent and selective nanomolar inhibitory activity against a wide range of human cancerous cell lines such as breast, leukemia, lung, colon, CNS, melanoma, ovarian, renal, and prostate. In this paper, we have reviewed the progresses and structural modification of 2-aminothiazole to pursuit potent anticancers and also highlighted in vitro activities and in silico studies. The information will useful for future innovation. Representatives of 2-aminothiazole-containing compounds classification.
Collapse
|
4
|
Efficient conversion of d-mannitol into 1,2:5,6-diacetonide with Aquivion-H as a recyclable catalyst. Carbohydr Res 2020; 499:108229. [PMID: 33401228 DOI: 10.1016/j.carres.2020.108229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 12/23/2020] [Accepted: 12/24/2020] [Indexed: 11/22/2022]
Abstract
Heterogeneous solid catalysis by the commercially available perfluorosulfonic ionomer Aquivion-H allowed 1,2:5,6-diacetonide of d-mannitol (1), immediate precursor of important unichiral C3-synthons, to be efficiently obtained from d-mannitol and 2,2-dimethoxypropane in DMF at room temperature. The 1,2-monoacetonide, whose intermediate formation is the rate-limiting step, could be almost completely converted into 1 with limited concurrent transformation of 1 into triacetonides. In line with recent literature reports, these results indicate that heterogeneous catalysis by Aquivion-H surpasses the performances of homogeneous acidic catalysis assuring, presumably for its peculiar morphology, a higher product selectivity. Easy recovery at the end of the reaction and recyclability are additional advantages of this solid acid catalyst.
Collapse
|
5
|
Bolchi C, Bavo F, Appiani R, Roda G, Pallavicini M. 1,4-Benzodioxane, an evergreen, versatile scaffold in medicinal chemistry: A review of its recent applications in drug design. Eur J Med Chem 2020; 200:112419. [PMID: 32502862 DOI: 10.1016/j.ejmech.2020.112419] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 04/14/2020] [Accepted: 05/02/2020] [Indexed: 12/11/2022]
Abstract
1,4-Benzodioxane has long been a versatile template widely employed to design molecules endowed with diverse bioactivities. Its use spans the last decades of medicinal chemistry until today concerning many strategies of drug discovery, not excluding the most advanced ones. Here, more than fifty benzodioxane-related lead compounds, selected from recent literature, are presented showing the different approaches with which they have been developed. Agonists and antagonists at neuronal nicotinic, α1 adrenergic and serotoninergic receptor subtypes and antitumor and antibacterial agents form the most representative classes, but a variety of other biological targets are addressed by benzodioxane-containing compounds.
Collapse
Affiliation(s)
- Cristiano Bolchi
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133, Milano, Italy
| | - Francesco Bavo
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133, Milano, Italy
| | - Rebecca Appiani
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133, Milano, Italy
| | - Gabriella Roda
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133, Milano, Italy
| | - Marco Pallavicini
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133, Milano, Italy.
| |
Collapse
|
6
|
Manaswiyoungkul P, de Araujo ED, Gunning PT. Targeting prenylation inhibition through the mevalonate pathway. RSC Med Chem 2020; 11:51-71. [PMID: 33479604 PMCID: PMC7485146 DOI: 10.1039/c9md00442d] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Accepted: 11/10/2019] [Indexed: 12/13/2022] Open
Abstract
Protein prenylation is a critical mediator in several diseases including cancer and acquired immunodeficiency syndrome (AIDS). Therapeutic intervention has focused primarily on directly targeting the prenyltransferase enzymes, FTase and GGTase I and II. To date, several drugs have advanced to clinical trials and while promising, they have yet to gain approval in a medical setting due to off-target effects and compensatory mechanisms activated by the body which results in drug resistance. While the development of dual inhibitors has mitigated undesirable side effects, potency remains sub-optimal for clinical development. An alternative approach involves antagonizing the upstream mevalonate pathway enzymes, FPPS and GGPPS, which mediate prenylation as well as cholesterol synthesis. The development of these inhibitors presents novel opportunities for dual inhibition of cancer-driven prenylation as well as cholesterol accumulation. Herein, we highlight progress towards the development of inhibitors against the prenylation machinery.
Collapse
Affiliation(s)
- Pimyupa Manaswiyoungkul
- Department of Chemistry , University of Toronto , 80 St. George Street , Toronto , Ontario M5S 3H6 , Canada
| | - Elvin D de Araujo
- Department of Chemical and Physical Sciences , University of Toronto Mississauga , 3359 Mississauga Rd N. , Mississauga , Ontario L5L 1C6 , Canada .
| | - Patrick T Gunning
- Department of Chemical and Physical Sciences , University of Toronto Mississauga , 3359 Mississauga Rd N. , Mississauga , Ontario L5L 1C6 , Canada .
- Department of Chemistry , University of Toronto , 80 St. George Street , Toronto , Ontario M5S 3H6 , Canada
| |
Collapse
|
7
|
Straniero V, Sebastián-Pérez V, Hrast M, Zanotto C, Casiraghi A, Suigo L, Zdovc I, Radaelli A, De Giuli Morghen C, Valoti E. Benzodioxane-Benzamides as Antibacterial Agents: Computational and SAR Studies to Evaluate the Influence of the 7-Substitution in FtsZ Interaction. ChemMedChem 2019; 15:195-209. [PMID: 31750973 DOI: 10.1002/cmdc.201900537] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 11/08/2019] [Indexed: 01/24/2023]
Abstract
FtsZ is a crucial prokaryotic protein involved in bacterial cell replication. It recently arose as a promising target in the search for antimicrobial agents able to fight antimicrobial resistance. In this work, going on with our structure-activity relationship (SAR) study, we developed variously 7-substituted 1,4-benzodioxane compounds, linked to the 2,6-difluorobenzamide by a methylenoxy bridge. Compounds exhibit promising antibacterial activities not only against multidrug-resistant Staphylococcus aureus, but also on mutated Escherichia coli strains, thus enlarging their spectrum of action toward Gram-negative bacteria as well. Computational studies elucidated, through a validated FtsZ binding protocol, the structural features of new promising derivatives as FtsZ inhibitors.
Collapse
Affiliation(s)
- Valentina Straniero
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Luigi Mangiagalli 25, 20133, Milano, Italy
| | | | - Martina Hrast
- Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia
| | - Carlo Zanotto
- Department of Medical Biotechnologies and Translational Medicine, Università degli Studi di Milano, Via Vanvitelli 32, 20129, Milano, Italy
| | - Andrea Casiraghi
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Luigi Mangiagalli 25, 20133, Milano, Italy
| | - Lorenzo Suigo
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Luigi Mangiagalli 25, 20133, Milano, Italy
| | - Irena Zdovc
- Faculty of Veterinary Medicine, University of Ljubljana, Gerbičeva 60, 1000, Ljubljana, Slovenia
| | - Antonia Radaelli
- Department of Medical Biotechnologies and Translational Medicine, Università degli Studi di Milano, Via Vanvitelli 32, 20129, Milano, Italy
| | | | - Ermanno Valoti
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Luigi Mangiagalli 25, 20133, Milano, Italy
| |
Collapse
|
8
|
Casiraghi A, Valoti E, Suigo L, Artasensi A, Sorvillo E, Straniero V. How Reaction Conditions May Influence the Regioselectivity in the Synthesis of 2,3-Dihydro-1,4-benzoxathiine Derivatives. J Org Chem 2018; 83:13217-13227. [DOI: 10.1021/acs.joc.8b02012] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Andrea Casiraghi
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, 20133 Milano, Italy
| | - Ermanno Valoti
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, 20133 Milano, Italy
| | - Lorenzo Suigo
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, 20133 Milano, Italy
| | - Angelica Artasensi
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, 20133 Milano, Italy
| | - Erica Sorvillo
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, 20133 Milano, Italy
| | - Valentina Straniero
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, 20133 Milano, Italy
| |
Collapse
|
9
|
Bolchi C, Bavo F, Regazzoni L, Pallavicini M. Preparation of enantiopure methionine, arginine, tryptophan, and proline benzyl esters in green ethers by Fischer–Speier reaction. Amino Acids 2018; 50:1261-1268. [DOI: 10.1007/s00726-018-2599-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 06/01/2018] [Indexed: 11/30/2022]
|
10
|
Straniero V, Casiraghi A, Fumagalli L, Valoti E. How do reaction conditions affect the enantiopure synthesis of 2-substituted-1,4-benzodioxane derivatives? Chirality 2018; 30:943-950. [PMID: 29752740 DOI: 10.1002/chir.22968] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 03/13/2018] [Accepted: 03/28/2018] [Indexed: 01/31/2023]
Abstract
Several biologically active compounds structurally include the enantiopure 2-substituted-1,4-benzodioxane scaffold. The straightforward racemization that affects reactions involving most of the common chemical reactives is thus a crucial issue. The developing of a completely stereo-controlled synthetic route that does not affect the enantiomeric excess is consequently mandatory. It is also important to set up a reliable chiral HPLC method, able to follow the reaction, and to improve the synthetic performances. Here, we report the chiral investigation of two different synthons, we specifically evaluated the synthetic pathways that could be run in order to afford them, avoiding the racemization processes, which could normally occur in basic conditions. In addition, we developed peculiar chiral HPLC methods in order to resolve the enantiomers, define the enantiomeric excess, and fully characterize these compounds.
Collapse
Affiliation(s)
- Valentina Straniero
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milan, Italy
| | - Andrea Casiraghi
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milan, Italy
| | - Laura Fumagalli
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milan, Italy
| | - Ermanno Valoti
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
11
|
Wang J, Yao X, Huang J. New tricks for human farnesyltransferase inhibitor: cancer and beyond. MEDCHEMCOMM 2017; 8:841-854. [PMID: 30108801 PMCID: PMC6072492 DOI: 10.1039/c7md00030h] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 02/15/2017] [Indexed: 12/18/2022]
Abstract
Human protein farnesyltransferase (FTase) catalyzes the addition of a C15-farnesyl lipid group to the cysteine residue located in the COOH-terminal tetrapeptide motif of a variety of important substrate proteins, including well-known Ras protein superfamily. The farnesylation of Ras protein is required both for its normal physiological function, and for the transforming capacity of its oncogenic mutants. Over the last several decades, FTase inhibitors (FTIs) were developed to disrupt the farnesylation of oncogenic Ras as anti-cancer agents, and some of them have entered cancer clinical investigation. On the other hand, some substrates of FTase were demonstrated to be related with other human diseases, including Hutchinson-Gilford progeria syndrome, chronic hepatitis D, and cardiovascular diseases. In this review, we summarize the roles of FTase in malignant transformation, proliferation, apoptosis, angiogenesis, and metastasis of tumor cells, and the recently anticancer clinical research advances of FTIs. The therapeutic prospect of FTIs on several other human diseases is also discussed.
Collapse
Affiliation(s)
- Jingyuan Wang
- Shanghai Key Laboratory of New Drug Design , School of Pharmacy , East China University of Science and Technology , 130 Mei Long Road , Shanghai 200237 , China . ; Tel: (+86)21 64253681
| | - Xue Yao
- Shanghai Key Laboratory of New Drug Design , School of Pharmacy , East China University of Science and Technology , 130 Mei Long Road , Shanghai 200237 , China . ; Tel: (+86)21 64253681
| | - Jin Huang
- Shanghai Key Laboratory of New Drug Design , School of Pharmacy , East China University of Science and Technology , 130 Mei Long Road , Shanghai 200237 , China . ; Tel: (+86)21 64253681
| |
Collapse
|
12
|
Moise IM, Ghinet A, Belei D, Dubois J, Farce A, Bîcu E. New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation. Bioorg Med Chem Lett 2016; 26:3730-4. [PMID: 27282741 DOI: 10.1016/j.bmcl.2016.05.074] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 05/24/2016] [Accepted: 05/25/2016] [Indexed: 10/21/2022]
Abstract
A new family of indolizine-chalcones was designed, synthesized and screened for the inhibitory potential on human farnesyltransferase in vitro to identify potent antitumor agents. The most active compound was phenothiazine 2a, exhibiting an IC50 value in the low nanomolar range, similar to that of known FTI-276, highly potent farnesyltransferase inhibitor. The newly synthesized indolizine-chalcones 2a-d constitute the most efficient inhibitors of farnesyltransferase bearing a phenothiazine unit known to date.
Collapse
Affiliation(s)
- Iuliana-Monica Moise
- 'Alexandru Ioan Cuza' University of Iasi, Faculty of Chemistry, Bd. Carol I nr. 11, 700506 Iasi, Romania
| | - Alina Ghinet
- 'Alexandru Ioan Cuza' University of Iasi, Faculty of Chemistry, Bd. Carol I nr. 11, 700506 Iasi, Romania; Hautes Etudes d'Ingénieur (HEI), Groupe HEI-ISA-ISEN, UCLille, Laboratoire de Pharmacochimie, 13 rue de Toul, F-59046 Lille, France; Inserm U995, LIRIC, Université de Lille, CHRU de Lille, Faculté de médecine-Pôle recherche, Place Verdun, F-59045 Lille Cedex, France
| | - Dalila Belei
- 'Alexandru Ioan Cuza' University of Iasi, Faculty of Chemistry, Bd. Carol I nr. 11, 700506 Iasi, Romania
| | - Joëlle Dubois
- Institut de Chimie des Substances Naturelles, UPR2301 CNRS, Centre de Recherche de Gif, Avenue de la Terrasse, F-91198 Gif-sur-Yvette Cedex, France
| | - Amaury Farce
- Inserm U995, LIRIC, Université de Lille, CHRU de Lille, Faculté de médecine-Pôle recherche, Place Verdun, F-59045 Lille Cedex, France; Faculté des Sciences Pharmaceutiques et Biologiques de Lille, 3 Rue du Pr Laguesse, B.P. 83, F-59006 Lille, France
| | - Elena Bîcu
- 'Alexandru Ioan Cuza' University of Iasi, Faculty of Chemistry, Bd. Carol I nr. 11, 700506 Iasi, Romania.
| |
Collapse
|
13
|
Moorthy NSHN, Sousa SF, Ramos MJ, Fernandes PA. Molecular dynamic simulations and structure-based pharmacophore development for farnesyltransferase inhibitors discovery. J Enzyme Inhib Med Chem 2016; 31:1428-42. [PMID: 26887913 DOI: 10.3109/14756366.2016.1144593] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Farnesyltransferase is one of the enzyme targets for the development of drugs for diseases, including cancer, malaria, progeria, etc. In the present study, the structure-based pharmacophore models have been developed from five complex structures (1LD7, 1NI1, 2IEJ, 2ZIR and 2ZIS) obtained from the protein data bank. Initially, molecular dynamic (MD) simulations were performed for the complexes for 10 ns using AMBER 12 software. The conformers of the complexes (75) generated from the equilibrated protein were undergone protein-ligand interaction fingerprint (PLIF) analysis. The results showed that some important residues, such as LeuB96, TrpB102, TrpB106, ArgB202, TyrB300, AspB359 and TyrB361, are predominantly present in most of the complexes for interactions. These residues form side chain acceptor and surface (hydrophobic or π-π) kind of interactions with the ligands present in the complexes. The structure-based pharmacophore models were generated from the fingerprint bits obtained from PLIF analysis. The pharmacophore models have 3-4 pharmacophore contours consist of acceptor and metal ligation (Acc & ML), hydrophobic (HydA) and extended acceptor (Acc2) features with the radius ranging between 1-3 Å for Acc & ML and 1-2 Å for HydA. The excluded volumes of the pharmacophore contours radius are between 1-2 Å. Further, the distance between the interacting groups, root mean square deviation (RMSD), root mean square fluctuation (RMSF) and radial distribution function (RDF) analysis were performed for the MD-simulated proteins using PTRAJ module. The generated pharmacophore models were used to screen a set of natural compounds and database compounds to select significant HITs. We conclude that the developed pharmacophore model can be a significant model for the identification of HITs as FTase inhibitors.
Collapse
Affiliation(s)
- N S Hari Narayana Moorthy
- a UCIBIO, REQUIMTE, Departamento de Química e Bioquímica, Universidade do Porto , 687, Rua do Campo Alegre , Porto , Portugal
| | - Sergio F Sousa
- a UCIBIO, REQUIMTE, Departamento de Química e Bioquímica, Universidade do Porto , 687, Rua do Campo Alegre , Porto , Portugal
| | - Maria J Ramos
- a UCIBIO, REQUIMTE, Departamento de Química e Bioquímica, Universidade do Porto , 687, Rua do Campo Alegre , Porto , Portugal
| | - Pedro A Fernandes
- a UCIBIO, REQUIMTE, Departamento de Química e Bioquímica, Universidade do Porto , 687, Rua do Campo Alegre , Porto , Portugal
| |
Collapse
|
14
|
Phenothiazine-based CaaX competitive inhibitors of human farnesyltransferase bearing a cysteine, methionine, serine or valine moiety as a new family of antitumoral compounds. Bioorg Med Chem Lett 2015; 25:4447-52. [DOI: 10.1016/j.bmcl.2015.09.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Revised: 09/03/2015] [Accepted: 09/04/2015] [Indexed: 01/08/2023]
|
15
|
Chiodini G, Pallavicini M, Zanotto C, Bissa M, Radaelli A, Straniero V, Bolchi C, Fumagalli L, Ruggeri P, De Giuli Morghen C, Valoti E. Benzodioxane-benzamides as new bacterial cell division inhibitors. Eur J Med Chem 2014; 89:252-65. [PMID: 25462242 DOI: 10.1016/j.ejmech.2014.09.100] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2014] [Revised: 09/09/2014] [Accepted: 09/15/2014] [Indexed: 11/30/2022]
Abstract
A SAR study was performed on 3-substituted 2,6-difluorobenzamides, known inhibitors of the essential bacterial cell division protein FtsZ, through a series of modifications first of 2,6-difluoro-3-nonyloxybenzamide and then of its 3-pyridothiazolylmethoxy analogue PC190723. The study led to the identification of chiral 2,6-difluorobenzamides bearing 1,4-benzodioxane-2-methyl residue at the 3-position as potent antistaphylococcal compounds.
Collapse
Affiliation(s)
- Giuseppe Chiodini
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133 Milano, Italy
| | - Marco Pallavicini
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133 Milano, Italy
| | - Carlo Zanotto
- Department of Medical Biothechnologies and Translational Medicine, Università di Milano, Via Vanvitelli 32, I-20129 Milano, Italy
| | - Massimiliano Bissa
- Department of Pharmacological and Biomolecular Sciences, Università di Milano, Via Balzaretti 9, I-2013 Milano, Italy
| | - Antonia Radaelli
- Department of Pharmacological and Biomolecular Sciences, Università di Milano, Via Balzaretti 9, I-2013 Milano, Italy; CNR Institute of Neurosciences, Cellular and Molecular Pharmacology Section, Università di Milano, Via Vanvitelli 32, I-20129 Milano, Italy
| | - Valentina Straniero
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133 Milano, Italy
| | - Cristiano Bolchi
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133 Milano, Italy
| | - Laura Fumagalli
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133 Milano, Italy
| | - Paola Ruggeri
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133 Milano, Italy
| | - Carlo De Giuli Morghen
- Department of Medical Biothechnologies and Translational Medicine, Università di Milano, Via Vanvitelli 32, I-20129 Milano, Italy; CNR Institute of Neurosciences, Cellular and Molecular Pharmacology Section, Università di Milano, Via Vanvitelli 32, I-20129 Milano, Italy
| | - Ermanno Valoti
- Dipartimento di Scienze Farmaceutiche, Università di Milano, Via Mangiagalli 25, I-20133 Milano, Italy.
| |
Collapse
|